Selectively Targeted TGF-β Activating Integrin, αvβ8 & αvβ8 in Solid Tumors to Increase Sensitivity to Checkpoint Inhibition Therapies
Time: 10:00 am
day: Conference Day Two
Details:
- Avoiding systemic toxicity by selective tatrgeting of TGF-β activating integrins in the tumor microenvironment with an oral small molecule inhibitor
- Anti-tumor activity from blocking distinct integrin-regulated TGF-β pathways on T-cells, tumor and stromal cells
- Activity as both a single agent in combination with checkpoint inhibitors in multiple animal models
